- Press releases

Asceneuron strengthens Board of Directors

Asceneuron today announced that Prof. Raymond Hill, former Executive Director, Licensing and External Research, Europe for Merck Sharp and Dohme, has been appointed to the board of directors. In addition, Dr. Franz Hefti, experienced in development of therapeutics for Alzheimer’s disease and former Chief Scientific Officer of Avid Radiopharmaceuticals before its acquisition by Eli Lilly in 2010, has been appointed as special advisor to the board.

- News

Asceneuron wins the Universal Biotech Innovation Prize 2014

Asceneuron wins the Universal Biotech Innovation Prize 2014. Open to young innovative companies, academic and private researchers, the Universal Biotech Innovation Prize aims to acknowledge on an international scale, the most innovative early stage projects in life sciences.

- News

CurePSP awards a research grant to Asceneuron

CurePSP awards a research grant to Asceneuron to study the role of O-linked protein glycosylation in the spread of tau pathology.

- Press releases

Dr. J. Donald deBethizy appointed to the Asceneuron’s Board of Directors

Asceneuron today announced the appointment of Dr. J. Donald deBethizy to its board of directors.

- Event

Asceneuron presents the novel M1-targeting compound ASN-51

Asceneuron presents the novel M1-targeting compound ASN-51 at the 11th International Conference on Alzheimer's and Parkinson's disease held 6-10 March 2013 in Florence, Italy.

- Press releases

Merck Serono announces the creation of Asceneuron

Merck Serono announces the creation of Asceneuron, the third Spin-Off company from its entrepreneur Partnership Program. Asceneuron will develop Merck Serono’s research programs in the area of Alzheimer’s disease.